Roche to build $467 million diagnostic manufacturing facility in China

5 November 2014

Swiss drug major Roche (ROG: SIX) is to invest 450 million Swiss francs ($467 million) in a new diagnostic manufacturing facility in China.

Built over the next three years, the facility will be located at the Suzhou Industrial Park in Suzhou. It sets out to address the growing demand for diagnostic tests in China and Asia Pacific, and will focus on producing immunochemistry and clinical chemistry tests, which are crucial to lab testing.

The site plans to employ a workforce of over 600 in the next several years.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK